Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ClearPoint Neuro, Inc. (Nasdaq: CLPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ClearPoint Neuro is a medical device company that develops device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine, and its filings offer detailed insight into this business.
Here you can review current and historical Forms 8-K, which ClearPoint Neuro uses to report material events such as preliminary unaudited financial results and significant transactions. For example, the company has filed 8-Ks announcing quarterly and annual financial results, as well as the completion of its acquisition of IRRAS Holdings, Inc., a transaction that expands ClearPoint Neuro’s presence in intracranial fluid management and neurocritical care.
Investors can also use this page to locate annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on revenue by category, operating expenses, and risk factors relevant to ClearPoint Neuro’s neurosurgical navigation, laser therapy, biologics and drug delivery, and intracranial fluid management activities. In addition, registration statements and related documents may describe share issuances connected to mergers or financing arrangements, such as the common stock issued in connection with the IRRAS merger.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of new disclosures. Real-time updates from EDGAR ensure that new CLPT filings, including Forms 4 for insider transactions and proxy materials related to governance and compensation, are available as they are posted. This page is intended as a central resource for analyzing ClearPoint Neuro’s regulatory history, capital structure changes, and material corporate events through its official SEC filings.
ClearPoint Neuro, Inc. provides an overview of its business and risks as a commercial-stage medical device company focused on minimally invasive neurosurgical procedures and biologics/drug delivery. It reports an aggregate market value of about $328 million for non-affiliate common stock as of June 30, 2025, and 29,663,875 shares outstanding as of March 6, 2026.
The company highlights two integrated components: neurosurgical devices, including the ClearPoint navigation platform, ClearPoint Prism Neuro Laser Therapy System, SmartFrame OR, and the newly added IRRAflow Active Fluid Exchange System from its 2025 IRRAS acquisition; and a growing biologics and drug delivery services business with more than 60 partners. It emphasizes multiple FDA clearances and a De Novo marketing authorization for the SmartFlow Neuro cannula in AADC deficiency, while summarizing extensive risk factors around integration of IRRAS, customer concentration, regulatory approvals, reimbursement, debt, and ongoing losses.
ClearPoint Neuro reported strong top-line growth for 2025 while remaining loss-making and investing heavily for future expansion. Total revenue rose to $37.0 million from $31.4 million, an 18% increase, with fourth-quarter revenue up to $10.4 million from $7.8 million, or 34% growth.
Biologics and drug delivery revenue grew 10% to $19.0 million, and neurosurgery navigation and therapy revenue rose 44% to $14.8 million, while capital equipment and software declined 18% to $3.1 million. Gross margin held at 61%, but operating expenses increased 21% to $46.9 million, driving a wider net loss of $25.5 million versus $18.9 million.
The company completed the IRRAS Holdings acquisition, added access to an extra $20.0 million under its Oberland Capital note facility, and ended 2025 with $45.9 million in cash and cash equivalents, up from $20.1 million. For 2026, ClearPoint Neuro projects revenue between $52.0 million and $56.0 million.
ClearPoint Neuro Chief Financial Officer Danilo D'Alessandro settled 32,627 restricted stock units into an equal number of shares of common stock on their scheduled vesting date.
Of these, 16,601 shares were delivered back to ClearPoint Neuro at
ClearPoint Neuro, Inc. CEO and President Joseph Burnett settled 84,829 restricted stock units, receiving the same number of common shares upon vesting. To cover tax withholding obligations, 43,161 common shares were delivered back to ClearPoint Neuro at
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall settled restricted stock units into common shares as part of scheduled vesting. Each unit converts into one share of common stock, and this transaction reflects the routine exercise or conversion of 30,995 restricted stock units.
In connection with the vesting, 15,151 shares of common stock were delivered back to ClearPoint Neuro at
ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin exercised and settled 26,101 restricted stock units into the same number of shares of common stock on their scheduled vesting date. Each unit represented a right to receive one share of common stock.
To cover tax withholding obligations tied to this vesting, 13,281 common shares were delivered back to ClearPoint Neuro at
ClearPoint Neuro, Inc. Schedule 13G shows that MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman beneficially own 1,729,611 shares of Common Stock, representing 6.1% of the class as of
ClearPoint Neuro, Inc.’s Chief Financial Officer Danilo D’Alessandro reported routine equity compensation activity involving restricted stock units. On March 11, 2026, 4,145 restricted stock units settled into the same number of common shares at a stated price of $0.00 per share, reflecting non-cash vesting.
In connection with this vesting, 2,109 common shares were delivered back to ClearPoint Neuro at $11.62 per share to satisfy tax withholding obligations, not as an open-market sale. After these transactions, D’Alessandro directly held 86,658 shares of common stock.
ClearPoint Neuro Chief Business Officer L. Jeremy Stigall settled restricted stock units into common shares. He exercised 8,291 restricted stock units into 8,291 shares of common stock. Of these, 3,224 shares at
ClearPoint Neuro CEO Joseph Burnett reported routine equity compensation activity. On March 6, 2026, 47,407 restricted stock units converted into the same number of shares of common stock at a stated price of $0.00 per share, reflecting scheduled vesting.
To cover tax obligations from this vesting, 22,709 common shares were delivered back to ClearPoint Neuro at $10.00 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, Burnett directly holds 54,232 common shares and indirectly holds 193,231 common shares through the Joseph M. Burnett Trust dated October 20, 2022.